Stocksigma LogoStocksigma Logo

Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY

Solara Active Pharma Sciences reported a strong Q2'27 performance, with revenue growing 33% YoY and 9% QoQ to INR 4,178 Mn

Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY

Solara Active Pharma Sciences Ltd 路 Press Release 路 16 Oct 2026, 7:18 pm

Solara Reports Record Q2'27 Results with EBITDA Surging 118% YoY Solara Active Pharma Sciences reported a strong Q2'27 performance, with revenue growing 33% YoY and 9% QoQ to INR 4,178 Mn. EBITDA surged 118% YoY and 21% QoQ to INR 769 Mn, expanding margins by 720 bps YoY to 18.4%. PAT turned around to INR 285 Mn from a loss of INR 101 Mn in Q2'26. Growth was driven by the base API business (revenue up 37% YoY to INR 3,273 Mn) and Ibuprofen narrowing EBITDA losses to INR 2 Mn. Net debt fell 19% to INR 5,000 Mn.

Original exchange filing (PDF)

More announcements from Solara Active Pharma Sciences Ltd

All Solara Active Pharma Sciences Ltd announcements